1. Home
  2. HIT vs IPHA Comparison

HIT vs IPHA Comparison

Compare HIT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIT
  • IPHA
  • Stock Information
  • Founded
  • HIT 1964
  • IPHA 1999
  • Country
  • HIT United States
  • IPHA France
  • Employees
  • HIT N/A
  • IPHA N/A
  • Industry
  • HIT Specialty Insurers
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIT Finance
  • IPHA Health Care
  • Exchange
  • HIT Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • HIT 150.6M
  • IPHA 160.1M
  • IPO Year
  • HIT 2024
  • IPHA 2019
  • Fundamental
  • Price
  • HIT $3.21
  • IPHA $1.93
  • Analyst Decision
  • HIT Strong Buy
  • IPHA Hold
  • Analyst Count
  • HIT 1
  • IPHA 2
  • Target Price
  • HIT $2.50
  • IPHA $2.00
  • AVG Volume (30 Days)
  • HIT 366.5K
  • IPHA 21.1K
  • Earning Date
  • HIT 11-16-2025
  • IPHA 09-17-2025
  • Dividend Yield
  • HIT N/A
  • IPHA N/A
  • EPS Growth
  • HIT N/A
  • IPHA N/A
  • EPS
  • HIT 0.02
  • IPHA N/A
  • Revenue
  • HIT $26,692,318.00
  • IPHA $14,839,695.00
  • Revenue This Year
  • HIT $70.02
  • IPHA $350.96
  • Revenue Next Year
  • HIT $63.39
  • IPHA $32.92
  • P/E Ratio
  • HIT $156.85
  • IPHA N/A
  • Revenue Growth
  • HIT 29.68
  • IPHA N/A
  • 52 Week Low
  • HIT $0.51
  • IPHA $1.29
  • 52 Week High
  • HIT $7.59
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • HIT 54.02
  • IPHA 46.96
  • Support Level
  • HIT $3.15
  • IPHA $1.77
  • Resistance Level
  • HIT $3.63
  • IPHA $1.91
  • Average True Range (ATR)
  • HIT 0.31
  • IPHA 0.11
  • MACD
  • HIT 0.00
  • IPHA -0.01
  • Stochastic Oscillator
  • HIT 55.08
  • IPHA 38.10

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: